Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares dropped 2.6% during mid-day trading on Monday . The company traded as low as $21.14 and last traded at $21.37, with a volume of 106,897 shares changing hands. The stock had previously closed at $21.95.

ATRA has been the topic of a number of research analyst reports. Jefferies Group reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, April 9th. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a research note on Friday, May 6th. Finally, JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and a consensus price target of $27.71.

The stock has a 50 day moving average of $21.09 and a 200-day moving average of $18.94. The company’s market cap is $616.56 million.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. During the same quarter in the previous year, the business posted ($0.42) EPS. Equities research analysts predict that Atara Biotherapeutics Inc. will post ($2.64) earnings per share for the current fiscal year.

In related news, insider Mitchall G. Clark sold 4,153 shares of the company’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $15.15, for a total value of $62,917.95. Following the transaction, the insider now directly owns 87,912 shares in the company, valued at $1,331,866.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Isaac E. Ciechanover sold 1,300 shares of the company’s stock in a transaction dated Tuesday, April 26th. The shares were sold at an average price of $20.12, for a total transaction of $26,156.00. Following the completion of the transaction, the chief executive officer now owns 217,321 shares in the company, valued at $4,372,498.52. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Atara Biotherapeutics stock. Jennison Associates increased its position in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 40.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 844,180 shares of the company’s stock after buying an additional 244,695 shares during the period. Jennison Associates owned approximately 2.95% of Atara Biotherapeutics worth $26,541,000 at the end of the most recent reporting period.

Atara Biotherapeutics, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate, PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.